Nerandomilast appears to reduce the risk of death in people with IPF and PPF, according to analyses of clinical trial data.
Columnist Sam Kirton's diagnostic journey was relatively short compared with that of other idiopathic pulmonary fibrosis (IPF) patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback